 |
3,4-diaminopyridine |
|---|---|
| Trade Name | |
| Orphan Indication | Lambert-Eaton Myasthenic Syndrome |
| USA Market Approval | USA |
| USA Designation Date | 1990-12-18 00:00:00 |
| Sponsor | Jacobus Pharmaceutical Company;37 Cleveland Avenue, P.O. Box 5290;Princeton, New Jersey, 08540 |
Related Access Program
David Lacomis – Lambert-Eaton Myasthenic Syndrome
Catalyst Pharmaceuticals, Inc. – Lambert-Eaton Myasthenic Syndrome
Ricardo Maselli – Lambert-Eaton Myasthenic Syndrome
Vern C. Juel, M.D. – Lambert-Eaton Myasthenic Syndrome
Tessa L Marburger – Lambert-Eaton Myasthenic Syndrome
University of Colorado, Denver – Lambert-Eaton Myasthenic Syndrome
University of Pittsburgh – Lambert-Eaton Myasthenic Syndrome
Catalyst Pharmaceutical Partners, Inc – Lambert-Eaton Myasthenic Syndrome
The Cleveland Clinic – Lambert-Eaton Myasthenic Syndrome